Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PRC2-mediated repression of SMARCA2 predicts EZH2 inhibitor activity in SWI/SNF mutant tumors.

Proceedings of the National Academy of Sciences of the United States of America - 14 Nov 2017

Januario Thomas, Ye Xiaofen, Bainer Russell, Alicke Bruno, Smith Tunde, Haley Benjamin, Modrusan Zora, Gould Stephen, Yauch Robert L

Abstract excerpt

Subunits of the SWI/SNF chromatin remodeling complex are frequently mutated in human cancers leading to epigenetic dependencies that are therapeutically targetable. The dependency on the polycomb repressive complex (PRC2) and EZH2 represents one such vulnerability in tumors with mutations in the SWI/SNF complex subunit, SNF5; however, whether this vulnerability extends to other SWI/SNF subunit mutations is not...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biphenyl Compounds
Share to Cathepsin B

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Enhancer of Zeste Homolog 2 Protein

Share to Morpholines

Share to Polycomb Repressive Complex 2

Share to Pyridones

Share to SMARCB1 Protein

Share to Tumor Burden

Source

Open in PubMed Open full text

Identifiers

PMID: 29087303
DOI: 10.1073/pnas.1703966114
PMCID: PMC5699030

Genes

SMARCA2
SMARCA4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PRC2-mediated repression of SMARCA2 predicts EZH2 inhibitor activity in SWI/SNF mutant tumors.PMID 29087303Read ↗

SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2.Semantic proximity Read ↗

SWI/SNF chromatin remodeling and human malignancies.Semantic proximity Read ↗

SWI/SNF chromatin remodeling complexes and cancer.Semantic proximity Read ↗

Mechanisms by which SMARCB1 loss drives rhabdoid tumor growth.Semantic proximity Read ↗

A Pan-Cancer Analysis of SMARCA4 Alterations in Human Cancers.Semantic proximity Read ↗

Residual complexes containing SMARCA2 (BRM) underlie the oncogenic drive of SMARCA4 (BRG1) mutation.Semantic proximity Read ↗

The role of SMARCA4 in lung cancerSemantic proximity Read ↗

PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated Cancers.Semantic proximity Read ↗

Mutation of SMARCA4 Induces Cancer Cell-Intrinsic Defects in the Enhancer Landscape and Resistance to Immunotherapy.Semantic proximity Read ↗

The spectrum of SWI/SNF mutations, ubiquitous in human cancers.Semantic proximity Read ↗

Molecular pathways: SWI/SNF (BAF) complexes are frequently mutated in cancer--mechanisms and potential therapeutic insights.Semantic proximity Read ↗

Dysregulation of SWI/SNF Chromatin Remodelers in NSCLC: Its Influence on Cancer Therapies including Immunotherapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.